Amarin To Report Fourth Quarter and Full Year 2018 Results and Host Conference Call on February 27, 2019 Read more about Amarin To Report Fourth Quarter and Full Year 2018 Results and Host Conference Call on February 27, 2019
Amarin to Present at the 8th Annual SVB Leerink Global Healthcare Conference Read more about Amarin to Present at the 8th Annual SVB Leerink Global Healthcare Conference
New REDUCE-IT™ Trial Data Showing the Total Reduction in Ischemic Events Accepted for Presentation at the American College of Cardiology’s 68th Annual Scientific Session Read more about New REDUCE-IT™ Trial Data Showing the Total Reduction in Ischemic Events Accepted for Presentation at the American College of Cardiology’s 68th Annual Scientific Session
Amarin Provides Preliminary 2018 Results and 2019 Outlook Read more about Amarin Provides Preliminary 2018 Results and 2019 Outlook
Amarin to Present at 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 Read more about Amarin to Present at 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019
Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference Read more about Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference
Amarin Prices Public Offering of American Depositary Shares Read more about Amarin Prices Public Offering of American Depositary Shares
Amarin Announces Proposed Public Offering of American Depositary Shares Read more about Amarin Announces Proposed Public Offering of American Depositary Shares
Amarin to Present at the Evercore ISI HealthCONx Conference Read more about Amarin to Present at the Evercore ISI HealthCONx Conference
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite E Read more about Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite E